Meeder Asset Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Meeder Asset Management’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,671	Closed	-$936	–	1822
2018 Q2	$936	Buy	5,671 +2,157	+61%	+$1.67K	﹤0.01%	1511
2018 Q1	$3K	Buy	3,514 +2,392	+213%	+$4.48K	﹤0.01%	1360
2017 Q4	$3K	Buy	1,122 +524	+88%	+$1.76K	﹤0.01%	1473
2017 Q3	$2K	Buy	598 +509	+572%	+$2.44K	﹤0.01%	1527
2017 Q2	$1K	Buy	89 +69	+345%	+$587	﹤0.01%	1625
2017 Q1	$0	Buy	+20	New	+$1.27K	﹤0.01%	1803

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Meeder Asset Management's ARGS Position: Q3 2018 in Review

Meeder Asset Management sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2018, closing a stake of 5,671 shares — an estimated $936 sold.

Meeder Asset Management first reported a position in ARGS in Q1 2017 and held it in 6 quarters. The position peaked at $3K in Q1 2018. 1 fund tracked by Wall St. Rank holds ARGS as of Q3 2018.

Meeder Asset Management reported no remaining Argos Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Meeder Asset Management sold 5,671 Argos Therapeutics, Inc. shares in Q3 2018, an estimated $936.
Meeder Asset Management first reported a position in Argos Therapeutics, Inc. in Q1 2017 and held it in 6 quarters.
Meeder Asset Management's Argos Therapeutics, Inc. position peaked at $3K in Q1 2018.
1 fund tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.